Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691071 | 0.92 | HSD11B1 (0.40) | HSD11B1GRIN2BGRIN2ALIPECYP4F2 | |
| SCHEMBL5689174 | 0.88 | HSD11B1 (0.40) | HSD11B1GRIN2BGRIN2ALIPENPC1 | |
| SCHEMBL5691280 | 0.87 | ALDH1A1 (0.36) | GRIN2BLIPEMGLLNPC1RAB9A | |
| SCHEMBL5688094 | 0.86 | HSD11B1 (0.43) | HSD11B1GRIN2BGRIN2ALIPECYP4F2 | |
| SCHEMBL5689664 | 0.85 | GRIN2B (0.39) | GRIN2BLIPEMGLL | |
| SCHEMBL5689349 | 0.84 | HSD11B1 (0.48) | HSD11B1GRIN2BGRIN2ALIPEMGLL | |
| SCHEMBL5689522 | 0.84 | CHRM5 (0.36) | GRIN2BLIPENPC1RAB9A | |
| SCHEMBL5691711 | 0.83 | HSD11B1 (0.35) | HSD11B1GRIN2BLIPECYP4F2CYP4A11 | |
| SCHEMBL5687404 | 0.82 | HSD11B1 (0.44) | HSD11B1GRIN2BGRIN2ALIPECYP4F2 | |
| SCHEMBL5690231 | 0.82 | HSD11B1 (0.44) | HSD11B1GRIN2BGRIN2ALIPECYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | LIPE, PNLIP, LIPC | HSD11B1 1283/4885GRIN2B 2588/4885GRIN2A 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.